TITLE

SPAIN SELECTS NOVANAX'S VLP FOR FLU VACCINE

PUB. DATE
August 2009
SOURCE
Worldwide Biotech;Aug2009, Vol. 21 Issue 8, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces Novavax Incorporated's initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals of Spain. The VLP technology will be used by ROVI to create a comprehensive influenza vaccine solution for the Spanish government. It describes the stock purchase agreement between Novavax and ROVI.
ACCESSION #
43476690

 

Related Articles

  • Novavax terminates negotiations with Rovi for flu vaccine partnership.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p15 

    The article reports on the discontinuation of the proposed flu vaccine partnership of Novavax Inc. and Rovi Pharmaceuticals.

  • Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries.  // Biomedical Market Newsletter;5/5/2011, p891 

    The article reports that Novavax Inc. signed an agreement with LG Life Sciences Ltd. (LGLS) to license its recombinant virus-like-particle (VLP) influenza vaccine technology. The agreement enables LGLS to manufacture, develop and market influenza vaccines using the VLP technology in South Korea...

  • Vaccine Report.  // BioPharm International;Aug2009, Vol. 22 Issue 8, p12 

    The article reports on the initial agreement of Novavax to license its virus-like particle (VLP) vaccine technology to Madrid, Spain-based Rovi Pharmaceuticals. ROVI will use the VLP technology to create a comprehensive influenza vaccine solution for the Spanish government. Morever, ROVI will...

  • CLINIC ROUNDUP.  // BioWorld Today;2/22/2010, Vol. 21 Issue 34, p7 

    The article reports on the preliminary safety and immunogenicity data from the 2009 A/H1N2 virus-like particle (VLP) pandemic influenza vaccine study by Novavax Inc. in Mexico.

  • Influenza Vaccine Trial Shows Positive Results for Older Adults.  // Journal of Gerontological Nursing;Sep2010, Vol. 36 Issue 9, p5 

    The article reports on a randomized, double blind, active-controlled Phase II study which found that an influenza vaccine from Novavax Inc. is safe and immunogenic against the 2009-2010 seasonal influenza virus strains in adults aged 60 and older. A discussion of the details of the trial, which...

  • An Alternative to the Scale-up and Distribution of Pandemic Influenza Vaccine. Robinson, James M. // BioPharm International;Jan2009 Supplement, p12 

    The article provides information on the novel, recombinant vaccine developed by Novavax Inc. that uses cell culture to rapidly produce three proteins specific to an emerging influenza strain. Novavax's production approach, which is based on baculovirus, will make it possible to provide vaccine...

  • PacificGMP and Novavax Collaborate on Large-Scale Influenza Vaccine Production. Holland-Moritz, Pam // BioPharm International;Apr2006, Vol. 19 Issue 4, p16 

    The article discusses the agreement between PacificGMP and Novavax. According to Leigh Pierce, President of the PacificGMP, Novavax is the closest in creating an accurate and effective flu vaccine with its virus-like particle technology. With PacificGMP's expertise in disposable manufacturing...

  • Novavax Reports Positive Results for its VLP-based Trivalent Flu Vaccine Candidate.  // BioPharm International;Jun2008, Vol. 21 Issue 6, p14 

    The article reports on the positive results of the virus-like particle (VLP)-based Trivalent Flu Vaccine Candidate of Novavax Inc. The findings allow the company to complete its planned investigational new drug (IND) application to support the Phase 2 clinical trial which is set to start in the...

  • Novavax reports positive results from influenza vaccine study.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p8 

    The article reports that biotechnology company Novavax Inc. reports positive results of its two-state pivotal study to evaluate the safety and immunogenicity of its unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine. According to the company, data shows that safety and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics